IP Library Patent Application 16833285
Patent Application
App. No. 16/833,285

INDUCED TISSUE REGENERATION USING EXTRACELLULAR VESICLES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/833,285
Abstract

Exosomes are generated from host embryonal carcinoma or embryonic progenitor cell lines and used for induced tissue regeneration. These inventive compositions and methods provide for induced tissue regeneration in aged or diseased mammalian tissues in vivo without the use of transgenically-expressed genes. Cells are reprogrammed to a prenatal, indeed a pre-fetal state, as indicated by for example in the case of many stromal cell types, by a decrease in the markers ADIRF and COX7A1.

Claims (15)

1 . A method for inducing cell or tissue regeneration, comprised of the steps: 1) isolating extracellular vesicles from host cells that display a pre-fetal pattern of gene expression; 2) contacting cells and/or tissue in vivo with the extracellular vesicles to restore a pre-fetal pattern of gene expression and induce tissue regeneration, but without reprogramming said cells and tissues to pluripotency.

2 . The method of claim 1 , wherein the more embryonic phenotype is indicated by a decrease in expression of COX7A1 from the reprogrammed cells and/or tissue.

3 . The method of claim 1 , wherein the cells are initially adult human cells.

4 . The method of claim 1 , wherein the contacted cells and/or tissue have a COX7A1 expression of less than 10% maximum by at least day 20.

5 . The method of claim 1 , wherein the extracellular vesicles are exosomes.

6 . The method of claim 1 , wherein the extracellular vesicles are derived from human embryonal carcinoma cells or embryonic progenitor cells.

7 . A method for inducing cell or tissue regeneration, comprised of the steps: 1) isolating extracellular vesicles from host embryonal carcinoma cells that are genetically-modified to overexpress LIN28B, SOX2, NANOG, OCT4 and MYC; 2) contacting cells and/or tissue in vivo with the extracellular vesicles to restore a pre-fetal pattern of gene expression and induce tissue regeneration, but without reprogramming said cells and tissues to pluripotency.

8 . The method of claim 7 , wherein the more embryonic phenotype is indicated by a decrease in expression of COX7A1 from the reprogrammed cells and/or tissue.

9 . The method of claim 7 , wherein the cells are initially adult cells.

10 . The method of claim 7 , wherein the contacted cells and/or tissue have a COX7A1 expression of less than 10% maximum by at least day 20.

11 . The method of claim 7 , wherein the extracellular vesicles are exosomes.

12 . A method for inducing cell or tissue regeneration, comprised of the steps: 1) isolating extracellular vesicles from host cells that display a pre-fetal pattern of gene expression; 2) introducing into said extracellular vesicles mRNAs for LIN28B, SOX2, NANOG, OCT4 and MYC; 3) contacting cells and/or tissue in vivo with the extracellular vesicles to restore a pre-fetal pattern of gene expression and induce tissue regeneration, but without reprogramming said cells and tissues to pluripotency.

13 . The method of claim 12 , wherein the more embryonic phenotype is indicated by a decrease in expression of COX7A1 from the reprogrammed cells and/or tissue.

14 . The method of claim 12 , wherein the cells are initially adult cells.

15 . The method of claim 12 , wherein the contacted cells and/or tissue have a COX7A1 expression of less than 10% maximum by at least day 20.

Assignments (1)
SECURITY INTEREST Recorded Nov 10, 2023
From: AGEX THERAPEUTICS, INC.; RECYTE THERAPEUTICS, INC.; REVERSE BIOENGINEERING, INC.
To: JUVENESCENCE LIMITED
Reel/Frame 065529/0594 →